Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Anne-Katrin Pröbstel; Gabrielle Rudolf; Klaus Dornmair; Nicolas Collongues; Jean-Baptiste Chanson; Nicholas S R Sanderson; Raija L P Lindberg; Ludwig Kappos; Jérôme de Seze; Tobias Derfuss

Originally published in Journal of neuroinflammation · 2015-03-08

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Antibodies against myelin oligodendrocyte glycoprotein (MOG) have been identified in a subgroup of pediatric patients with inflammatory demyelinating disease of the central nervous system (CNS) and in some patients with neuromyelitis optica spectrum disorder (NMOSD). The aim of this study was to examine the frequency, clinical features, and long-term disease course of patients with anti-MOG antibodies in a European cohort of NMO/NMOSD. Findings Sera from 48 patients with NMO/NMOSD and 48 patients with relapsing-remitting multiple sclerosis (RR-MS) were tested for anti-aquaporin-4 (AQP4) and anti-MOG antibodies with a cell-based assay. Anti-MOG antibodies were found in 4/17 patients with AQP4-seronegative NMO/NMOSD, but in none of the AQP4-seropositive NMO/NMOSD (n = 31) or RR-MS patients (n = 48). MOG-seropositive patients tended towards younger disease onset with a higher percentage of patients with pediatric ( Conclusions MOG-seropositive patients show a diverse clinical phenotype with clinical features resembling both NMO (attacks mainly confined to the spinal cord and optic nerves) and MS with an opticospinal presentation (positive OCBs, brain lesions).

Discussion

We identified four patients with antibodies against native conformational MOG in a blinded cohort of 48 NMO/NMOSD patients. All four patients fulfilled the diagnostic criteria of NMO at disease onset (1/4) or at the time of second territorial involvement (3/4). Anti-MOG antibodies were detected in 4 out of 48 NMO/NMOSD patients and 4 out of 17 AQP4-seronegative patients. These findings are in line with other recent reports that identified antibodies against MOG in a subgroup of AQP4-seronegative patients with NMO/NMOSD [8-10,12-16] (Table 2).

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?